

Product List

2023/2024



FINISHED PRODUCT LIST

Active substance	Dosage form	Strengths	EU-CTD dossier
Aripiprazole	Tablets	5 / 10 / 15 / 30 mg	✓
Atorvastatin + Ezetimibe FDC	Capsules	10+10 / 20+10 / 40+10 mg	✓
Bisoprolol + Amlodipine FDC	Tablets	5+5 / 5+10 / 10+5 / 10+10 mg	✓
Cilostazol	Tablets	50 / 100 mg	✓
Dimetindene (OTC)	Gel	1mg / g	✓
Donepezil	Film-coated tablets	5 / 10 mg	✓
Ezetimibe	Tablets	10 mg	✓
Hemorrhoids rectal (MD)	Ointment		✓
Hemorrhoids rectal (MD)	Suppository		✓
Hyaluronic acid + Lactic acid (MD)	Vaginal gel	75 g, 7x5 g	✓
Nitroglycerin spray	Aerosol	10 g / 22 ml	✓
Ramipril + Amlodipine FDC	Capsules	5+5 / 5+10 / 10+5 / 10+10 mg	✓
Ramipril + Bisoprolol FDC	Capsules	5+5 / 5+10 / 10+5 / 10+10 mg	✓
Rivaroxaban	Tablets	2,5 / 10 / 15 / 20 mg	✓
Rosuvastatin	Film-coated tablets	5 / 10 / 20 / 40 mg	✓
Rosuvastatin + Ezetimibe FDC	Capsules	5+10 / 10+10 / 20+10 / 40+10 mg	✓
Rosuvastatin + Ramipril FDC	Capsules	10+5 / 10+10 / 20+5 / 20+10 mg	✓
Sunitinib	Capsules	12,5 / 25 / 50 mg	✓
Ramipril + Indapamide SR FDC	Capsules	5 + 1,5 / 10 + 1,5 mg	Q1 2024
Sacubitril + Valsartan FDC	Film-coated tablets	24 + 26 / 49 + 51 / 97 + 103 mg	Q1 2024
Rosacea base (cosmetics)	Cream		Q1 2024
Rosacea protection (cosmetics)	Cream		Q1 2024
Hyaluronic acid + Panthenol (cosmetics)	Cream		Q1 2024
Ibrutinib	Film-coated tablets	140 / 280 / 420 / 560 mg	Q4 2026
Dapagliflozin	Film-coated tablets	5 / 10 mg	Q4 2024
Dapagliflozin + Atorvastatin FDC	Capsules	10 + 10 / 10 + 20 / 10 + 40 mg	Q1 2026
Empagliflozin + Atorvastatin FDC	Capsules	11 + 10 / 10 + 20 / 10 + 40 mg	TBD
Dapagliflozin + Ramipril FDC	Capsules	10 + 5 / 10 + 10 mg	TBD
Dapagliflozin + Bisoprolol	Capsules	10 + 2,5 / 10 + 5 / 10 + 10 mg	Q1 2025
Empagliflozin + Ramipril FDC	Capsules	11 + 5 / 10 + 10 mg	TBD
Dapagliflozin + Rosuvastatin FDC	Capsules	10 + 10 / 10 + 20 / 10 + 40 mg	TBD
Empagliflozin + Rosuvastatin FDC	Capsules	11 + 10 / 10 + 20 / 10 + 40 mg	TBD

HIGHLY POTENT PORTFOLIO

Active substance	Dosage form	Strengths	EU-CTD dossier availability
Abemaciclib	Tablets	50 / 100 / 150 mg / 200 mg	Q3 2026
Acalabrutinib	Capsules	100 mg	Q3 2030
Alectinib	Capsules	150 mg	Q3 2028
Filgotinib	Tablets	100 mg	Q3 2030
Osimertinib	Tablets	40 / 80 mg	Q2 2028
Ozanimod	Capsules	0,92 mg (+0,23 mg, +0,46 mg)	Q3 2030
Palbociclib	Film-coated tablets	75 / 100 / 125 mg	Q2 2025
Ribociclib	Tablets	200 mg	Q3 2028
Upadacitinib	PR tablets	15 / 30 mg	Q2 2030

ACTIVE PHARMACEUTICAL INGREDIENTS

COMMERCIALY AVAILABLE

INN	Quality	CEP / BR DMF / CN DMF / US DMF / JP DMF / EU DMF
Allopurinol	EP/JP	JP DMF / CEP
Amlodipine besilate	EP	CN DMF / BR DMF / CEP
Bisoprolol fumarate	EP	CEP
Carvedilol form II	EP	CEP
Chlorpromazine HCl	EP	EU DMF / BR DMF / JP DMF / CEP
Clomiphene citrate	EP	EU DMF
Crotamiton	EP/USP/CP	CN DMF / US DMF / CEP
Donepezil HCl form I	USP/EP	EU DMF
Ethacrynic acid	EP/USP	CEP / US DMF
Ketoprofen	EP	CEP
Levomopromazine maleate	EP	EU DMF / BR DMF / CEP
Methyldopa	EP	CEP
Nifedipine	EP	EU DMF
Nitrendipine	EP	CEP
Promethazine HCl	EP/USP	US DMF / BR DMF / CEP
Quetiapine fumarate	EP	EU DMF / CEP
Ramipril	EP	CEP
Rivaroxaban	EP	EU DMF
Tofisopam	JP/ICH	JP DMF / EU DMF

SOON COMMERCIALY AVAILABLE

INN	Quality	DMF, CEP
Duloxetine	EP	CEP (2024 Q4)
Levocetirizine diHCl	EP	CEP (2025 Q1)

All the activities (development, testing, production) concerning the active pharmaceutical ingredients listed in the API product catalog are performed in countries where such activities are not prevented by third parties' rights, especially patent rights, and in compliance with the IP laws of the respective country. None of the products will be offered / supplied to countries in which these activities might be prevented by valid IP rights. However, the final legal responsibility lies exclusively on the buyer. Egis does explicitly exclude any and all legal responsibility for the correctness and for the use of the information in the API product catalog.

DRUG SUBSTANCE DEVELOPMENT LIST

ADVANCED STAGE

Kilolab process or pilot scale up is ready, including PAR measurements at least for the last two chemical steps and the DS purification step. Where we have EGIS own DS form, we have originator's form too. Documentation is available in Hungarian.

INN	Sample	Quality	Egis own DS form (besides originator's form)	Technical package
Abemaciclib	✓	ICH	x	✓
Avapritinib*	✓	ICH	✓	✓
Baricitinib*x	✓	ICH	✓	✓
Dapagliflozin-2-propanediol***	✓	ICH	x	✓
Empagliflozin**	✓	ICH	x	✓
Ibrutinib**x	✓	ICH	x	✓
LCZ 696***	✓	ICH	x	✓
Osimertinib	✓	ICH	x	✓
Palbociclib***x	✓	ICH	✓	✓
Pimavanserin*	✓	ICH	✓	✓
Pomalidomide*	✓	ICH	x	✓
Siponimod*	✓	ICH	x	✓
Tofacitinib*	✓	ICH	x	✓

*: kilolab process development is completed

** : kilolab process development is completed, pilot scale-up in progress

***: kilolab process development is completed, pilot scale-up is completed

x: Products developed under Strategic Cooperation with Polpharma

EARLY STAGE

INN	Sample	Egis own form
Acalabrutinib#	x	x
Alectinib##	✓	✓
Blarcamesine##	✓	✓
Brexpiprazole##	✓	✓
Deucravacitinib#	✓	✓
Elafibranor##	x	x
Epacadostat##	x	x
Evenamide##	✓	✓
Evobrutinib##	✓	✓
Filgotinib##	✓	✓
Fruquintinib##	✓	✓
Lasmiditan##	✓	✓
Lumateperone##	✓	✓
Mavacamten##	✓	✓
Mirabegron##	✓	✓
Ozanimod##	✓	✓
Ribociclib##	✓	✓
Solriamfetol##	✓	✓
Upadacitinib#	✓	x
Venetoclax##	✓	✓

#: lab synthesis development is in progress

##: lab synthesis development is completed

WISH LIST

INN
Abrocitinib
Brigatinib
Darolutamide
Entrectinib
Ponesimod
Resmetirom
Troriluzole
VK-2809

Egis Pharmaceuticals PLC HQ

Address: 1106 Budapest, Keresztúri út 30-38, Hungary

Phone: +36 1 803-5555

Web: int.egis.health

E-mail: mailbox@egis.hu

Finished Product Sales: fpd.opr@egis.hu

Purchasing and Active Ingredients Sales: bulk.opr@egis.hu

Egis Pharmaceuticals PLC Trade Center

Address: 1134 Budapest, Lehel utca 11-15., Hungary

Phone: +36 1 803-2222

